Tempol inhibits TGF-β and MMPs upregulation and prevents cardiac hypertensive changes

International Journal of Cardiology

Volumn 165, Issue 1, 2013, Pages 165-173

  Rizzi, Elen ^a   Castro, Michele M ^a   Ceron, Carla S ^a   Neto Neves, Evandro M ^a   Prado, Cibele M ^a   Rossi, Marcos A ^a   Tanus Santos, Jose E ^a   Gerlach, Raquel F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antioxidant; Cardiac hypertrophy; Hypertension; MMP 2; Reactive oxygen species; TGF

Indexed keywords

HYDROETHIDINE; MATRIX METALLOPROTEINASE; SUPEROXIDE; TEMPOL; TRANSFORMING GROWTH FACTOR BETA; GELATINASE A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTERY CONSTRICTION; ARTICLE; BLOOD PRESSURE MONITORING; DRUG EFFECT; ENZYME ACTIVITY; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; IMMUNOFLUORESCENCE TEST; MALE; MORPHOMETRICS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UPREGULATION; ZYMOGRAPHY; ARTERY CATHETERIZATION; BIOSYNTHESIS; CAROTID ARTERY; CHEMICAL PARAMETERS; CONTROLLED STUDY; ENZYME INDUCTION; GELATINOLYTIC ACTIVITY; HEART CONTRACTION; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; OUTCOME ASSESSMENT;

ANIMALS; ANTIOXIDANTS; CARDIOMEGALY; CARDIOTONIC AGENTS; CYCLIC N-OXIDES; HYPERTENSION; MALE; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; RATS; RATS, WISTAR; SPIN LABELS; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 84876110850     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.08.060     Document Type: Article

References (40)

1. D. Levy, M.G. Larson, R.S. Vasan, W.B. Kannel, and K.K. Ho The progression from hypertension to congestive heart failure Jama 275 1996 1557 1562
2. B.C. Berk, K. Fujiwara, and S. Lehoux ECM remodeling in hypertensive heart disease J Clin Invest 117 2007 568 575
3. L.H. Opie, P.J. Commerford, B.J. Gersh, and M.A. Pfeffer Controversies in ventricular remodelling Lancet 367 2006 356 367
4. M.A. Rossi Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans J Hypertens 16 1998 1031 1041
5. M.A. Rossi, and L.C. Peres Effect of captopril on the prevention and regression of myocardial cell hypertrophy and interstitial fibrosis in pressure overload cardiac hypertrophy Am Heart J 124 1992 700 709
6. B. Lopez, A. Gonzalez, R. Querejeta, M. Larman, and J. Diez Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure J Am Coll Cardiol 48 2006 89 96
7. Y. Iwanaga, T. Aoyama, Y. Kihara, Y. Onozawa, T. Yoneda, and S. Sasayama Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats J Am Coll Cardiol 39 2002 1384 1391
8. F.G. Spinale Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function Physiol Rev 87 2007 1285 1342
9. H. Takenaka, Y. Kihara, Y. Iwanaga, Y. Onozawa, S. Toyokuni, and T. Kita Angiotensin II, oxidative stress, and extracellular matrix degradation during transition to LV failure in rats with hypertension J Mol Cell Cardiol 41 2006 989 997
10. M.R. Bergman, J.R. Teerlink, and R. Mahimkar Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction Am J Physiol Heart Circ Physiol 292 2007 H1847 H1860
11. W. Wang, C.J. Schulze, W.L. Suarez-Pinzon, J.R. Dyck, G. Sawicki, and R. Schulz Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury Circulation 106 2002 1543 1549
12. G. Sawicki, H. Leon, and J. Sawicka Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2 Circulation 112 2005 544 552
13. D.A. Siwik, and W.S. Colucci Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium Heart Fail Rev 9 2004 43 51
14. W. Zhao, T. Zhao, Y. Chen, R.A. Ahokas, and Y. Sun Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats Mol Cell Biochem 317 2008 43 50
15. S. Rajagopalan, X.P. Meng, S. Ramasamy, D.G. Harrison, and Z.S. Galis Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability J Clin Invest 98 1996 2572 2579
16. T. Hu, R. Luan, and H. Zhang Hydrogen peroxide enhances osteopontin expression and matrix metalloproteinase activity in aortic vascular smooth muscle cells Clin Exp Pharmacol Physiol 36 2009 626 630
17. R.M. Liu, and K.A. Gaston Pravia Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis Free Radic Biol Med 48 2010 1 15
18. K. Kameda, T. Matsunaga, and N. Abe Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling Eur Heart J 24 2003 2180 2185
19. M.J. Cox, U.A. Hawkins, B.D. Hoit, and S.C. Tyagi Attenuation of oxidative stress and remodeling by cardiac inhibitor of metalloproteinase protein transfer Circulation 109 2004 2123 2128
20. C.S. Wilcox Effects of tempol and redox-cycling nitroxides in models of oxidative stress Pharmacol Ther 126 2010 119 145
21. Z. Luo, Y. Chen, and S. Chen Comparison of inhibitors of superoxide generation in vascular smooth muscle cells Br J Pharmacol 157 2009 935 943
22. M.M. Castro, E. Rizzi, and L. Figueiredo-Lopes Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats Atherosclerosis 198 2008 320 331
23. M.M. Castro, E. Rizzi, and G.J. Rodrigues Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension Free Radic Biol Med 46 2009 1298 1307
24. H.C. Salgado, G.M. Simoes, V.J. Santana Filho, Dias da Silva VJ, M.C. Salgado, and R. Fazan Jr. Negative inotropic and lusitropic effects of intravenous amiodarone in conscious rats Clin Exp Pharmacol Physiol 34 2007 870 875
25. E.M. Neto-Neves, C.A. Dias-Junior, and E. Rizzi Metalloproteinase inhibition protects against cardiomyocyte injury during experimental acute pulmonary thromboembolism Crit Care Med 39 2011 349 356
26. D. Sorescu, and K.K. Griendling Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure Congest Heart Fail 8 2002 132 140
27. S. Rosenkranz TGF-beta1 and angiotensin networking in cardiac remodeling Cardiovasc Res 63 2004 423 432
28. M. Luchtefeld, K. Grote, and C. Grothusen Angiotensin II induces MMP-2 in a p47phox-dependent manner Biochem Biophys Res Commun 328 2005 183 188
29. J. Friedman, S. Kraus, Y. Hauptman, Y. Schiff, and R. Seger Mechanism of short-term ERK activation by electromagnetic fields at mobile phone frequencies Biochem J 405 2007 559 568
30. T. Okamoto, T. Akaike, T. Sawa, Y. Miyamoto, A. van der Vliet, and H. Maeda Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation J Biol Chem 276 2001 29596 29602
31. S. Viappiani, A.C. Nicolescu, and A. Holt Activation and modulation of 72 kDa matrix metalloproteinase-2 by peroxynitrite and glutathione Biochem Pharmacol 77 2009 826 834
32. E.R. Frears, Z. Zhang, D.R. Blake, J.P. O'Connell, and P.G. Winyard Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite FEBS Lett 381 1996 21 24
33. D.J. Brown, B. Lin, M. Chwa, S.R. Atilano, D.W. Kim, and M.C. Kenney Elements of the nitric oxide pathway can degrade TIMP-1 and increase gelatinase activity Mol Vis 10 2004 281 288
34. S. Donnini, M. Monti, and R. Roncone Peroxynitrite inactivates human-tissue inhibitor of metalloproteinase-4 FEBS Lett 582 2008 1135 1140
35. E. Rizzi, M.M. Castro, and C.M. Prado Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension J Card Fail 16 2010 599 608
36. M.L. Martinez, M.M. Castro, and E. Rizzi Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats Eur J Pharmacol 591 2008 224 230
37. M.L. Martinez, L.F. Lopes, and E.B. Coelho Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension J Cardiovasc Pharmacol 47 2006 117 122
38. M.L. Martinez, E. Rizzi, and M.M. Castro Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats Eur J Pharmacol 599 2008 110 116
39. D.M. Marcal, E. Rizzi, and A. Martins-Oliveira Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension Naunyn Schmiedebergs Arch Pharmacol 383 2011 35 44
40. C.S. Ceron, M.M. Castro, and E. Rizzi Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension Br J Pharmacol 160 2010 77 87